Dr. Dino Dina named president of Dynavax.SAN DIEGO--(BW HealthWire)--May 20, 1997--Dynavax Technologies Corp. Wednesday announced that Dino Dina, M.D., has been named president. Dr. Dina previously served as president of Chiron Vaccines, formerly the Biocine Company, and brings 15 years of management and product development experience to the company. "We are extremely pleased that Dr. Dina has joined Dynavax," said Daniel Janney, chairman of the board and principal with Alta Partners. "He is one of the most talented and experienced executives in the vaccine business, with a strong background in genetics -- a great combination for the leader of a DNA-based immunotherapy company. "Dynavax's platform technology is conducive to corporate partnering and Dr. Dina's strong relationships and experience in this area will be particularly beneficial." Dina joins Dynavax after 15 years with Chiron Corp., where he progressed from director of virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression to his most recent position as president of Chiron Vaccines. Dina directed the Biocine Company from its inception in 1987 as a joint venture between Chiron and Ciba-Geigy Ltd. (now Novartis). Biocine became Chiron Vaccines in 1995. Over the last 10 years, Chiron Vaccines grew into a business unit with two European subsidiaries, more than 1,400 employees and more than $300 million in end sales worldwide. Under his direction the vaccine division received the first-ever approval of an adjuvanted Influenza vaccine influenza vaccine Flu vaccine A vaccine recommended for those at high risk for serious complications from influenza: > age 65; Pts with chronic diseases of heart, lung or kidneys, DM, immunosuppression, severe anemia, nursing home and other chronic-care in Italy, successfully completed development for the first genetically engineered genetically engineered adjective Recombinant, see there Pertussis vaccine pertussis vaccine n. A vaccine containing inactivated Bordetella pertussis bacteria, often used in the diphtheria, tetanus toxoids, and pertussis vaccine to immunize against whooping cough. Also called whooping cough vaccine. and conducted clinical trials for vaccines to prevent HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , Herpes Simplex Type II, Cytomegalovirus cytomegalovirus (sī'təmĕg'əlōvī`rəs), member of the herpesvirus family that can cause serious complications in persons with weakened immune systems. and NonA-NonB Hepatitis. The virology group he directed was responsible for several key scientific findings, including the discovery, cloning and sequencing of the Hepatitis C virus
Dina received his M.D. from the University of Genova Medical School in Italy, and has numerous publications in leading scientific journals and magazines. Dynavax is an early-stage biotechnology company funded by Alta Partners, InterWest Partners, Sanderling and Forward Ventures, utilizing novel technology in the field of DNA-based immunotherapies to develop products to prevent and treat allergies, infectious diseases and cancer. The company was founded on a series of discoveries made by Drs. Dennis Carson and Eyal Raz while at the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. . CONTACT: Dynavax Technologies Corp., San Diego Dino Dina, 619/625-4242 or Mentus, San Diego Linda Seaton, 619/455-5500 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion